Skip to main content
Premium Trial:

Request an Annual Quote

LifeLabs Offering NanoString's Breast Cancer MDx in Canada

NEW YORK( GenomeWeb) – LifeLabs Medical Laboratory Services today said it is offering NanoString's Prosigna Breast Cancer Prognostic Gene Signature Assay in Canada. 

LifeLabs said it is the first clinical lab in the country to offer the test, which is approved by Health Canada and cleared by the US Food and Drug Administration

Prosigna is a gene expression-based test that evaluates the genetic profile of cells found in breast cancer tissue to assess the 10-year risk of recurrence of cancer in post-menopausal, hormone-receptor positive women with early-stage breast cancer. LifeLabs said Prosigna is the only molecular test in its class to be approved by Canadian regulators. 

"This test can help physicians determine whether breast cancer patients will benefit from chemotherapy treatment or whether other treatment options are more appropriate," LifeLabs CEO Sue Paish said in a statement. "By providing this molecular test inCanada, physicians can make quicker treatment decisions by having faster access to important clinical information."